DiaMedica Therapeutics Inc. (DMAC)
$7.82-4.63%Close
BUYRECOVERY · day 49
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $421M
- Beta
- 0.91
- P/E (TTM)
- -10.86
- Short % float
- 20.62%
- Days to cover
- 23.3
- SI change
- +1.7%
- 1W
- -3.81%
- 1M
- +19.39%
- vs SPY 1W
- -3.67%
- vs SPY 1M
- +16.88%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 19
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-46.6%
REV YoY-
ROE-77.7%
EPS YoY-
ROA-83.4%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-10.86
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B10.99
P/FCF-
EV/EBITDA-11.12
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.48
ALTMAN Z-
CURR RATIO6.72
ND/EBITDA-
BETA0.91
Company news
FAQ
- What is LOPJLB’s current signal on DMAC?
- LOPJLB’s latest quantitative signal on DiaMedica Therapeutics Inc. (DMAC) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is DMAC in?
- DiaMedica Therapeutics Inc. (DMAC) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does DiaMedica Therapeutics Inc. (DMAC) do?
- DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type …